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Abstract 
 
This project was conducted to develop a policy proposal that would increase HIV testing after 
evaluating current Kentucky Law and Regulations, current health insurance laws, studies on 
acceptability of different HIV test, barriers to testing from both providers and 
patients/individuals, and factors associated with positive likelihood of HIV testing. Based on 
these findings a proposal was developed that would require changing Kentucky regulations on 
providers communicating test results to patients, change in what form HIV testing would be 
covered under certain insurances, develop incentives for patients to be tested and report their 
results to their provider (and hence increasing surveillance data), and selecting the most 
acceptable, convenient and affordable at-home/self-testing option to be covered. The proposal 
addresses the barriers of anonymity/privacy (to an extent), anxiety with waiting for results, ED 
missed opportunities for testing, counselling, venipuncture, and more. The proposal in its entirety 
is more of an expansion on what can be done about HIV testing rates more so than replacing 
what is in place. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords: HIV testing, HIV, Kentucky HIV, Rural Kentucky HIV, HIV acceptability, HIV 
policy, testing barriers. 
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Objective 
 
To evaluate the current Kentucky law on HIV testing and reporting, and evaluate studies 
on HIV testing acceptability in order to develop and propose changes to Kentucky law on HIV 
testing, the testing process itself, and create innovative interventions in order to increase HIV 
testing in rural Kentucky and among people who inject drugs.  
 
Introduction 
 
An estimated 1.1 million people live in the United States with HIV. Of those people, 
about 15%, that is, 1 in 7 did not know they were infected (1). In a study conducted in 2015 an 
estimated discounted lifetime cost for persons who become HIV infected at age 35 was $326,500 
(2). Approximately 60% of this cost stems from the cost of the antiretroviral medication, 15% is 
for other non-retroviral medications and 25% of the expenditure is spent on non-drug costs (2). 
For individuals who are not infected but are high risk for transmission, the discounted lifetime 
cost estimate was $96,700 (2). The medical cost saved by avoiding one HIV infection was 
projected to be $229,800 (2). The cost saved would reach $338,400 if all HIV-infected 
individuals presented early and remained in care (2). Savings may be underestimated if taking 
into account avoided secondary infections, and overestimated if HIV infections are temporarily 
delayed (2). These numbers are extremely important from a financial burden standpoint. The cost 
of the disease will affect how the infected behave. For example, many individuals will elect to 
stop taking the medication simply because they cannot afford it. This will affect their general 
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health, increase risk of transmission, and overall add to the national medical expenditure when 
they are forced to utilize hospitals due to subsequent complications. 
The burden of HIV diagnosis in the United States from 2012 to 2016 has been relatively 
stable however the burden of disease varies greatly between regions. In 2017, the south made up 
52% (19,968) of the new diagnosis in the US, followed by the West (7270; 19%), the Northeast 
(6,011; 16%), and the Midwest (5,032; 13%). US dependent areas made up 458 (1%) of new 
HIV diagnoses. The rates (per 100,000 people) of HIV diagnoses were 16.1 in the South, 12.3 in 
the US dependent areas, 10.6 in the Northeast, 9.4 in the West, and 7.4 in the Midwest. The 
majority of people who receive an HIV diagnosis live in urban areas. However, in the South 23% 
of new HIV diagnoses are in suburban and rural areas in a much higher proportion than in the 
Northeast and West. Furthermore, the larger geographically dispersed populations of people 
living with HIV in the South creates a challenging setting for prevention and treatment (3). This 
is complicated even more by the ever growing opioid epidemic. 
In 2016, people who inject drugs accounted for 9% of new diagnoses of HIV in the 
United States (4)(5); 8.2% of cases among men and 13.2% of cases among women were 
transmitted via intravenous drug use (4)(5). According to the CDC it is estimated that there has 
been 8.6 new diagnosis of HIV for every 100,000 people in Kentucky in 2016. Data from 2015 
demonstrated that 336 of new HIV diagnosis occurred in Kentucky (5). Approximately 10% of 
these new cases in males and 12.5% of the new cases in females were attributed to injection drug 
use (6). According to data from Substance Abuse and Mental Health Service Administration 
(SAMHSA) National Surveys on Drug Use and Health (NSDUH), in Kentucky, an estimated 
14,000 people, aged 12+, were known to have used heroin in the past year, and 35,000 people, 
aged 12+, were estimated to use methamphetamine in the past year (7). Methamphetamine and 
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heroin are both injectable drugs that significantly contribute to the spread of diseases such as 
HIV and hepatitis C along with causing overdoses and deaths. This makes injection drug use a 
priority behavior for intervention from a public health standpoint. 
In the South, the HIV epidemic is mostly found in the urban areas, however the region 
does have a greater number of new diagnoses in rural and suburban areas when compared to the 
rest of the country (8). In addition to the infectious epidemic, the growing rate of injection drug 
use in the United States will lead to an increase in bloodborne diseases in this region, including 
HIV. Several services are in place to reduce the growing incidence of transmission among people 
who inject drugs (PWID), these include: syringe service programs (9, 10), medication assisted 
therapy (11), addiction treatment and rehabilitation centers. In addition to these services, 
continuous surveillance of these reportable diseases is also important. Continuous surveillance 
can help identify individuals in communities that would require treatment services, initiate 
contact investigations to identify their sexual and needle sharing partners resulting in potential 
treatment of those found to be infected or prevention of transmission through counselling or 
PReP.  Unfortunately, many communities do not have access to facilities offering these services 
and/or have low HIV testing rates (8) despite having a very high rate of injection drug use (12). 
Unlike testing for other infectious diseases, testing for HIV involves possible benefits as 
well as social, economic, and legal consequences that typically are not apparent or known to an 
individual considering testing. HIV testing is the first step to health-preserving treatment but can 
also be the basis for criminal prosecution for those who are sexually active, and be used to 
exclude individuals positive for HIV. Though there are federal and state laws to limit 
discriminatory actions, the ability to enforce these laws usually involves free legal services that 
are increasingly difficult to obtain and sometimes not available (13). If available to the 
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individual, such information would understandably influence their decision to test, and if they 
decide to test it will affect when and how they test. The ‘how’ refers to getting tested 
anonymously vs through a confidential testing process that reports results and identifying 
information to the state but is not publicly available (13). 
 In Kentucky, the Cabinet for Health and Family Services (CHFS) is responsible for 
implementing a statewide program for the detection, prevention and control of communicable 
diseases and to adopt regulations specifying the information and time period for reporting 
sexually transmitted disease. In Kentucky, according to the regulatory statute KRS 214.625 The 
physician, advanced practice registered nurse: that orders testing for HIV must inform the patient 
of positive test and must provide information and counselling to the patient about the diagnosis 
and the known medical implications of the condition or refer the patient to another appropriate 
professional or healthcare facility for information and counselling. This must be done in person. 
In regards to reporting, according to 902 KAR 2:020 physicians and mid-level providers, 
hospitals, and laboratories are required to report cases to CHFS. The CHFS and local health 
departments STD personnel under KRS 211.180 also have the authority to conduct investigations 
of people known to be or reasonably suspected of being infected with HIV, and carry out their 
duty of controlling and preventing a disease by directing reasonably suspected people undergo 
medical examinations, including laboratory testing. These statutes and regulations were put in 
place to help keep the public healthy but certain attributes as this article will describe later can be 
barriers to individuals and problems for the general population. 
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Methods of Analysis 
 
In this paper we will be using the Bardach guide for analysis of state regulations 
regarding HIV testing in Kentucky. The first step involves identifying a problem.  
The second step involves gathering information. This was done by creating a literature 
review. The information gathered included but was not limited to: incidence rates in urban, 
suburban, and rural areas of the South, the growing use of injection drug use and its role in the 
transmission of HIV, services in place to decrease transmission of HIV in Kentucky, and a 
review of several studies on HIV testing acceptability. 
The third step in this paper will be to compare results from our study, performed at the 
University of Kentucky by Dr. April Young, to other studies on HIV testing acceptability and 
different test. The information gathered from this study comparison will be used to construct an 
alternative method of testing and regulatory action, and responsibilities. 
The final steps would be to establish criteria in which the proposed alternatives would 
excel, project or estimate the outcomes of the proposed changes, compare the pros and cons of 
the alternative solutions, and the current methods of testing, regulatory actions and 
responsibilities. 
The search strategy used to identify studies used for review and comparison included studies that 
observed the acceptability of HIV testing using at home test, comparison of HIV testing 
acceptability between different types of test and settings, associations with opting in or out of 
home testing, burden of HIV, and disparities among certain communities as they relate to HIV 
surveillance. The Kentucky regulatory statutes on HIV testing and reporting, and previous 
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rulings on cases involving HIV transmission were used to as resources into the legal aspects of 
HIV. 
 
The Problem 
 
For this paper the issues that will be focused on are the low HIV testing rates (based on the high 
rate of late testers) in rural Kentucky, an area with high prevalence of people who inject drugs. 
 
According to an assessment at the county-level, there are approximately 220 counties in 26 states  
that are vulnerable to rapid dissemination of HIV with a high incidence and prevalence of HCV 
among people who inject drugs (14). A large proportion of the 220 counties were rural (14). Out 
of the 220 counties, 54 of these counties identified to be at high risk for rapid dissemination of 
bloodborne disease were in Kentucky, with 43 of these found in eastern Kentucky’s Appalachian 
region (14). In Scott County, Indiana, rapid dissemination of HIV took place among people who 
inject drugs highlighting the lack of previously mentioned primary and secondary preventive 
services and the need for harm-reduction strategies (15). In order to prevent another incident 
such as the one that took place in Scott County, steps need to be taken, first of which is to 
identify who is infected. In Kentucky this is a problem as HIV testing rates in the United States 
Southern region is low; lifetime HIV testing rates ranged from 43.6% among those living in most 
urban areas to 32.2% among those living in most rural areas (16). According to the United States 
Preventive Services Task Force (USPSTF) guidelines, it is recommended that adolescents and 
adults aging from 15 to 65 years old be screened for HIV; those who are out of this age range 
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who are at high risk (IVDU, MSM, unprotected sex, sex with bisexuals, IVDU, or HIV-positive 
individuals, and those involved in sex trafficking) should also be screened. 
 
It is difficult to assess HIV testing rates in a community, partly because negative results are not 
required by law to be reported, due to the sensitivity of the information may not be volunteered, 
and lastly self-testing kits are not reported to the government. A surveillance technique to gauge 
appropriately timed testing is to look at the rates of late-to-test individuals. According to the 
CDC, late-to-test individuals are those who tested positive for HIV and were diagnosed within a 
year with acquired immune deficiency syndrome AIDS (17). Surveillance of these individuals is 
important because though it is not a direct measurement of testing rates it gives an idea of who 
and where people are not getting tested until it is too late. It is estimated that 15% of individuals 
with HIV do not know they have it/ not been tested but 40 percent of transmissions originate 
from these individuals (4). In Kentucky, from January 1, 2006 through June 30, 2016 a total of 
3,614 new cases of HIV were diagnosed (17). Of those, 1,214 (34%) had been diagnosed with 
AIDS within a year, and 883 (24.4%) had concurrent diagnosis, that is they were diagnosed with 
AIDS within 30 days of being diagnosed with HIV (17). For comparison, in 2014 among those 
diagnosed with HIV, 23% were considered late diagnosis and were positive for AIDS in the 
United States (18). This shows a disparity of early testing in Kentucky when compared to the rest 
of the United States. A closer look demonstrates a disparity of late testers within the state of 
Kentucky. Most new cases of HIV are found in the urban areas of the south which is true for 
Kentucky as well, however, what is shocking is the higher rate of concurrent diagnosis in the 
rural eastern Appalachia region ranging from 35% – 43% in contrast to the rest of the state 
ranging from 21% - 30% (17). This disproportionate amount of late testers can be due to several 
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challenges such as decreased access to testing, decreased testing by providers, lack of knowledge 
of the disease and decreased acceptability of the testing/screening method. 
 
Some of these challenges were identified in a 2003 cross-sectional study performed in Seattle, 
Washington. A survey conducted at three sites in Seattle (Downtown Needle Exchange site, the 
Public Health-Seattle and King County STD clinic, and MSM sex venues) identified barriers to 
traditional HIV testing. Based on the survey, fear of results and societal discrimination were 
important factors serving as personal barriers to participants (19). The most reported barrier 
associated with laws and policy was having to report positive results, without anonymity (19). 
There was also a lot of concern about how difficult it would be to get a job or health insurance 
(19), note this was prior to the Affordable Care Act that made it illegal for insurance companies 
to base rates or deny coverage based on pre-existing conditions. Barriers associated with the 
testing process and counselling included the act of giving blood via venipuncture, anxiety 
waiting for results, and an aversion to speaking to counsellors (19).  
 
Though there is literature that discuss the lower rates of HIV testing in rural America (8, 16), 
there appears to be little research involving the acceptability of at-home HIV testing in these 
regions. As the barriers to getting tested includes lack of anonymity, social discrimination, 
waiting for results, and not wanting to speak with a counsellor, (19) Dr. Young’s study aimed to 
explore the feasibility of at-home HIV testing among rural Kentuckians while providing 
anonymity, reduced steps required by individuals for diagnosis, and not requiring individuals to 
speak with a counsellor. It is believed that this should increase acceptability of home HIV-
testing, thereby increasing diagnostic, and treatment rates. 
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Results 
Within the investigations into the trends of HIV testing for eastern Kentucky, it was discovered 
that having ever been tested for HIV using any modality, and having ever been diagnosed with a 
sexually transmitted infection was associated with consenting for at-home testing. Similar 
findings are found in other studies investigating the trends of HIV testing (20, 21). A cross-
sectional study conducted in China from 2011-2012, demonstrated that among MSM participants 
and non-MSM participants who volunteered for counselling and testing, having ever been tested 
for HIV was associated with increased acceptability of at-home testing (21). The testing offered 
in this study was not a blood specimen test like the study done in rural Kentucky, and a blood 
specimen at-home test was not offered during this test for comparison. In 2014, another study 
performed in China demonstrated higher rates of self-testing acceptance (using blood-specimen 
or oral fluid) was associated with having HIV test done within the last 12 months, and having 
ever been tested for a sexually transmitted infection, not necessarily diagnosed with an STI (20). 
This corresponds with the study conducted in rural Kentucky as both studies’ survey was not 
conducted on a face to face basis however this sample is not representative of our population. 
Interestingly, the study performed in Seattle, had the opposite results of our findings (19). The 
Seattle study previously mentioned demonstrated that participants that have never tested before 
or within 12 months are more likely to opt for the at home testing using oral fluid or blood 
sampling. Overall, participants in the Seattle study found the option to mail in a finger-prick 
specimen and receive a result via phone call the least attractive method of testing, as only 1% 
chose this option (19). These studies suggest that the factors playing a role in acceptability of at-
home testing varies, possibly according to geographic location but all the studies when compared 
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to the study of rural Kentucky suggest that oral fluid home testing is preferred, and would most 
likely be a better option for at-home testing if public stakeholders wish to increase testing in their 
communities. 
In the study of rural Kentucky the largest barrier to acceptance of the at-home HIV testing was 
the uncertainty in the accuracy of the test. In our sample, the main reason for those who were 
unlikely to want at-home HIV testing was uncertainty about the accuracy of the test. Other 
common barriers mentioned were that participants would rather have the testing process done in 
person, and/or they didn’t feel at risk for HIV. A survey conducted in San Francisco also 
identified that accuracy as a reason for not opting for the at home test (22). Other reasons 
included in the San Francisco study that were also related to getting the test done in person 
included: trust, and the sense of safety and professionalism when with a healthcare provider (22). 
This is a frequently seen theme among those who choose not to use the at-home testing. This 
does not necessarily mean that the individuals are not willing to get tested, it simply suggest that 
some people would rather be tested at a clinic by a healthcare provider they trust. This means 
that in order to reach a wider audience, actions made by public health officials should also make 
sure to have multiple options of testing to increase community participation.  
The Law 
The Kentucky laws in regards to HIV testing are designed to help decrease the rate of 
transmission of HIV and increase treatment of HIV-positive individuals however after reviewing 
several articles these statutes may actually be part of the problem behind decreased rates of HIV 
testing and high rates of late-testers in rural Kentucky. The regulatory statute KRS 214.625 
explains how the ordering physician or advanced practice registered nurse for HIV testing must 
be the one to notify the patient of a positive test. This is likely to ensure that the patient is 
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notified of a life-threatening disease so that they may take steps toward treatment. However it is 
also possible that this may deter providers in certain specialties from ordering the test. For 
example, in a study performed within a multi-location health care system in New York, the 
emergency department had the lowest odds of ordering an HIV [screening] test during the same 
encounter, for NG/CT testing (23). The article states that reasons ED providers may not order 
test is multifactorial including need of a private place to provide testing and counselling, and cost 
of coordinating follow-up for individuals with positive test (23,24), which can be time 
consuming and work against the need to minimize ED wait times. Part of KRS 214.625 is that if 
an individual is found to have a positive test, in addition to being notified by the provider who 
ordered the test, the provider must also provide information and counsel the patient about their 
diagnosis or refer them to another appropriate professional for counselling, this must be done in 
person. This requires providers such as the ones in the ED to spend additional time with the 
patient, in addition to possibly waiting for a private room to be available, further discouraging 
providers to perform what has been referred to as a preventive medicine test (24). 
The Test 
A review study of several reports measuring the acceptability of HIV self-testing demonstrated 
that self-testing was highly acceptable (28). Participants in the study included men who have sex 
with men (MSM), heterosexual men or women or bisexual or lesbian woman (HTX), transgender 
(TG), female sex workers (FSW), and people who inject drugs (PWID) (28). Comprehensive 
comments from participants of the study illustrated interest in self-testing because of its 
convenience and privacy (28). Majority of the studies in the review involved MSM participants, 
only one study specifically accounted for PWID (19). In the review an acceptability rate of  > 
67% was considered high, only 8 of the 14 studies demonstrated high acceptability (14). The 
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literature review demonstrates high acceptability among the high risk MSM population, however 
it is lacking in studies assessing acceptability among PWID.  
 
In the study of rural Kentucky, a history of ever injecting drugs was positively associated with 
participants agreeing to opt for at-home testing. A 2003 survey of three different sites in the city 
of Seattle (a STD clinic, sex venue, and needle exchange site), found that the preferred method 
of testing varied by site (19). People who inject drugs were found at all sites with the majority of 
people who inject drugs at the needle exchange site (19). The study demonstrated that most 
needle exchange site participants preferred the urine test (23%), more than the rapid clinic-based 
serum test (22.1%), standard serum test (20%), oral fluid test (19.3%), rapid home (oral fluid) 
self-test (13.8%), and home specimen collection (1.4%) (19). The Seattle study appears to infer 
that people who inject drugs are less likely to choose home self-testing over other modalities. 
This does not correspond with the study conducted in rural Kentucky. Being that this Seattle 
study was done in a city, the type of testing preferred may differ based on region. This means 
that methods used by agents of public health to increase HIV screening/testing would need to 
devise a strategy based on the type of community in question. 
According to the 2016 Kentucky HIV/AIDS Surveillance Report from the Cabinet for Health 
and Family Resources, only 16 out of 54 counties comprising the Appalachia counties are 
offered oral swab rapid HIV – 1/2 antibody test from agencies sponsored by the HIV Prevention 
Program at the Department for Public Health (17). The remaining 38 counties are offered finger 
stick rapid HIV 1/2 antibody test; none are offered both; none provide home self-testing (17). 
Alternative methods of HIV testing need to be implemented in order to increase access to HIV 
testing in rural areas. On July 3, 2012 the OraQuick In-Home HIV Test, a rapid home-use HIV 
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screening test kit, was approved by the Food and Drug Administration (25). This test does not 
require a medical provider, counsellor, or sending results to a laboratory for analysis (25). The 
test screens your oral sample for antibodies in the saliva and epithelial cells gathered from 
swabbing your upper and lower gums (25). The sample is immersed in a tube with a developing 
solution for about 20-40 minutes. If a single line appears that signifies a negative result, if two 
lines appear that means the HIV antibodies were detected and the individual possibly has HIV 
(25). In Singapore, a study looking at the acceptability of using OraQuick test at home 
demonstrated a high acceptability rate among participants willing to purchase the over the 
counter test, 87.4% (26). However it is very important to remember that the OraQuick test does 
have the potential to have false positives since it indirectly test for HIV by detecting antibodies 
and not a component of the virus itself (25). This means that a confirmatory test must be 
obtained. Individuals will need to have access, and mode of transportation to a healthcare facility 
(health department or clinic) for confirmatory testing. This can inadvertently delay diagnosis, 
subsequent counselling and treatment ultimately increasing risk of transmission. The study 
conducted by Dr. April Young at the University of Kentucky performed an acceptability study 
using the Home Access HIV-1 Test System, an over the counter dried blood spot test. The test 
uses finger stick blood dried on a special material that is mailed with a confidential and 
anonymous personal identification number to a laboratory for testing (27). Like OraQuick, the 
Home Access HIV-1 test for antibodies, the difference is that if it is positive, the same sample 
can be mailed to a testing center for a confirmatory test (27), addressing the barrier posed by lack 
of transportation, accessibility to testing site, and lack of anonymity. The study was conducted in 
rural Kentucky and had an acceptability rate of only 63%, which is not considered high when 
comparing to other studies (28). 
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Table 1. Home Testing Kits 
Test 
Category 
HIV 
Screening 
Tests 
Detects 
IgG 
Detects 
IgM 
Whole 
Blood 
Specimen 
Uses oral 
fluid 
specimen 
Accuracy 
(Sensitivity/ 
Specificity) 
Cost 
Ag/Ab 
(reported 
separately) 
rapid test 
Determine 
HIV-1/2 
Ag/Ab 
Combo 
✓ ✓ ✓  Ab: 99.4% / 
99.2% 
Ag:0.000% 
/ 98.3% 
(29) 
$24.98 
ELISA/Ab 
test 
Home 
Access 
HIV-1 Test 
System 
? ✓ ? ✓ ✓  >99.9 / 
>99.9 (30) 
? 
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Ab rapid 
test 
DPP HIV-1/2 
Assay 
✓  ✓ ✓ Oral: 98.9% 
/ 99.9% 
Blood: 
99.8% / 
99.8 % (31) 
$25.13 
 
 
HIV 1/2 
STAT-PAK 
✓  ✓  99.7% / 
99.9% (32) 
$25.18 
INSTI HIV-
1/HIV-2 
Antibody 
Test 
✓ ✓ ✓  >99% / 
>99% (33) 
$26.04 
OraQuick 
ADVANCE 
Rapid HIV-
1/2 
Antibody 
Test 
✓ ✓ ✓ ✓ Oral: 99.3% 
/ 99.8% 
Blood: 99.6% 
/ 100% (34) 
$34.99 
Reveal G4 
Rapid HIV-1 
Antibody 
Test 
✓  ✓  99.8 % / 
99.7% (35) 
$23 
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SURE 
CHECK HIV 
1/2 Assay 
✓  ✓  99.7% / 
99.9% (36) 
$400.00 
Uni-Gold 
Recombigen 
HIV-1/2 
✓ ✓ ✓  100% / 
99.7% (34) 
$26.80 
 
Alternative Solutions 
Changes to KRS 214.625 
The proposed changes to the laws most likely to improve HIV testing rates would be:  
To not make providers who ordered the test the sole designee to notify patients of their 
test results and provide counselling, if result are found to be positive. The patient may be 
presented with the option to learn about his results and receive counselling from the 
ordering provider or another provider or qualified professional. 
UPDATE: This proposal has been passed as state legislation. 
At Home vs On Site 
On Site 
Currently in the state of Kentucky, government sponsored agencies, and private clinics do not 
perform or administer at-home self-testing HIV screening. The reason for this is likely due in 
part to Kentucky HIV law prior to 2019: A provider must counsel a patient in regards to a 
positive result in person. Most screening test performed in the clinical setting for HIV are done 
using a blood sample that is sent for testing in a laboratory. If the test is positive the patient 
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should be brought in to discuss the results in person and be counselled on treatment, risk 
reducing behaviors including vaccinations, and offer a referral to speak with a counsellor for 
support. In the public health facility setting, oral fluid test or blood test or both are offered and 
under the KRS 214.645 statute this test can be offered anonymously or confidentially, the latter 
meaning gathering of identifying data. 
The benefits of at site testing are quite numerous. First, HIV testing is a preventive medicine 
measure and per the Affordable Care Act is covered by insurance. However, this coverage may 
vary depending on what kind of plan you have. This means that the cost of HIV testing 
performed on site is either subsidized or completely covered without out-of-pocket cost to the 
individual as in the case of Medicare (Plan B) and Medicaid (varies by state) (37,38). Second, 
with on-site testing providers are able to provide in person interpretations of results for patients 
and provide counselling, as mandated by the Kentucky statutes. This addresses two barriers to 
testing identified in the rural Kentucky population: uncertainty of test accuracy, and performing 
test in a non-clinical setting. Questions about the accuracy of the test would be answered by 
trained professionals, and individuals would have the peace of mind that the test would be done 
by a professional in a clinical setting. 
Another benefit to testing on site is that upon learning of their results, if an individual is found to 
be positive there is usually a direct link to further testing, treatment, and resources to assist the 
individual with obtaining these services. 
More importantly being tested on-site allows for a very important task to occur that is key in 
reducing transmission, gathering infection data. Gathering HIV infection data allows for the state 
to monitor disease rates in the state and identify disparities or outbreaks among regions. This 
information in turn affects decisions on where to focus efforts of intervention. By law, in the 
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private clinical setting an individual deemed to be positive (after confirmatory testing) is to be 
reported to the health department, this allows for the health department to conduct contact 
investigations. Contact investigation allow health departments to obtain information from the 
infected individual about who they may have had contact with in the form of needle-sharing, 
sexual activity or other blood or body fluid exchanges. This information is then used to contact 
these individuals notifying them of being exposed and to get tested without revealing the identity 
of who exposed them. The goal is to have these individuals tested and treated early if positive, 
also go through counselling, treatment, and conduct investigation into their contacts if necessary. 
This will further reduce the risk of transmission. 
Unfortunately, there are some downsides to onsite testing as well. First it incorporates one of the 
main barriers to getting tested for HIV which is the lack of anonymity. In the private practice 
setting, where the medical home model is growing, the individual will be revealing to that 
practice’s employees that they have HIV. The practice is also obligated to report the infected 
individual’s condition to the state who in-turn may indirectly reveal his condition to sexual 
partners and needle-sharing partners through phone calls warning them of having a recent HIV-
positive partner and to seek testing, which could possibly reveal the HIV positive individual. 
This is not always the case, as mentioned before health departments in Kentucky are able to offer 
fully anonymous testing, however this in itself causes an issue in limiting how many people are 
contacted for testing and treatment. Along with anonymity, having to speak with a counsellor 
was known to be a barrier and getting counselled is built in to part of being tested on-site. 
Though it wasn’t specifically mentioned as a barrier to testing, the legal ramifications for being 
HIV positive under “lack of anonymity” is a significant barrier. For example, under Kentucky’s 
“wanton endangerment” law it is illegal to have sexual relations without notifying your partner 
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of having the disease (39). Another example is that if positive and a healthcare worker the state 
can limit what an individual can do at their job (40). 
At Home 
In contrast to on site testing, home testing addresses the barrier of lack of anonymity and 
convenience. Home testing also allows individuals to bypass the counselling portion of being 
tested, which was identified as a barrier to being tested. 
Though counselling was identified as being a barrier to getting tested, individuals who opt for 
home testing and do not seek counselling put themselves at a disadvantage and are likely to put 
themselves and others in danger. They may misinterpret results as diagnostic of having 
HIV/AIDS, they miss out on learning about what behaviors improve their health and reduce risk 
of infection to others, may not learn about the legal ramifications of the diagnosis, and miss out 
on patient navigation services to treatment. From a financial stand point most insurances 
including Medicaid or Medicare do not cover at-home testing (37,38). There are some exceptions 
such as Aetna who will cover HIV testing prescribed by a physician (41) but due to Kentucky 
law requiring a provider to deliver the results in person and counsel in person it is not likely a 
medical provider will prescribe a home test. Therefore the cost of the home HIV test will be on 
the individual. In addition to the negative aspects for an individual, home testing adversely 
impacts the function of the public health department. Home testing does not allow for the state 
recording of individuals that have tested positive. This can cause underestimation of incidence or 
prevalence and mask an outbreak or disparity in a region. The lack of being able to follow up 
with these individuals is that contact investigations can also not be completed allowing for 
further increased risk for transmission.  
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Table 2. Comparison of site testing vs home testing. 
 
 
Rapid Saliva & Blood vs Urine vs Conventional Blood Screening Test 
There are many different types of screening testing for HIV. This section will explore the 
advantages and the disadvantages of using certain tests. Please refer to Table 1. 
Conventional Blood Screening Test 
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Conventional blood screening test of HIV involves venipuncture to obtain blood and sending that 
blood to a laboratory for analysis, the result usually takes up to a week or two for results to get 
back. In comparison to the rapid test that is a very long time and which has been shown to be a 
barrier to individuals getting tested (19,42). 
Rapid Test 
For the most part all rapid test are accurate, convenient, relatively fast, and comparatively 
affordable. 
Rapid Saliva Antibody Test 
There are two options for test that use saliva sample for testing: DPP HIV-1/2 Assay, and the 
OraQuick ADVANCE Rapid HIV-1/2 Antibody Test. The benefits of both are that the method of 
obtaining a sample is painless, and if need be can also use blood sample instead. OraQuick has 
an advantage as it can theoretically detect HIV antibodies (Ab) closer to time of infection than 
the DPP screening test after being infected. This is because the OraQuick test for both IgM, 
earlier produced Ab, and IgG, later produced Ab. DPP screening test only detects IgG. You may 
use a blood sample to increase the sensitivity and specificity in both test but the same theory in 
regards to time to detection applies (43). The DPP screening test is however cheaper costing $10 
- $15 less per test than OraQuick (Table 1). Unfortunately neither are as sensitive near the time 
of infection as conventional lab test using blood samples (43). A common theme in most studies, 
including that performed by Dr. Young, was that home blood-testing correlated with a lower 
acceptability rate, most preferred oral-fluid for home testing (19, 20, 22). 
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Rapid Blood Only Antibody Test 
For the rapid test using blood samples only, the two options I would consider are the INSTI HIV-
1/HIV-2 and the Reveal G4 Rapid HIV-1 Antibody Test. The great part about these test are that 
they are the quickest to perform only taking two minutes to run (43). They are more sensitive and 
specific in detecting antibodies closer to the time of infection than using a sample of saliva. Like 
the OraQuick, INSTI test checks for both IgM and IgG, while the Reveal G4 Rapid like the DPP 
test checks for just IgG. This means that INSTI is more sensitive near time of infection than the 
Reveal G4 Rapid. INSTI test also is FDA approved to detect Ab against HIV1 and HIV2 while 
Reveal G4 Rapid is only FDA approved for detecting HIV-1. However Reveal G4 Rapid is $3 
cheaper per test than the INSTI. 
Rapid Blood Only Antibody/Antigen Test 
The only rapid test available that detects both the antibody and, in theory, an antigen of HIV is 
the Determine HIV-1/2 Ag/Ab Combo. This test detects both Abs IgM and IgG as well as the 
p24 antigen (Ag) which is present prior to any Ab detectability. However studies have shown 
that Ag sensitivity portion of the test is zero when testing before seroconversion (producing 
antibodies) making the Ag component obsolete (31). The test also takes longer to perform than 
the rapid blood only Ab test, requiring a run time of up to at least 20 minutes (43). 
Urine Test 
The urine test is another non-invasive test that can be used to screen for HIV however its sensitivity and 
specificity have been shown to be lower than that of the saliva and blood test and has only been FDA 
approved for HIV-1 screening (44). 
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Table 3. Comparison of Modes of testing. 
 
 
Proposed Solution 
 
The purpose of this paper is to evaluate current laws, practices and studies to identify barriers to 
getting HIV testing, promote HIV testing, and use this information in to ultimately develop a 
change in policy in state law or health care insurance and subsequently change testing practices 
in order to increase testing rates in rural Kentucky. 
 
The Kentucky statutes were bound to change, the rule of having the ordering provider have to be 
the one to notify and/or counsel the patient in person is not compatible with the popular medical 
home model being practiced by outpatient groups. The medical home model is form of practice 
where all practitioners are able to provide care to a patient of the medical group. This way if one 
physician is unavailable to take care of a patient a colleague is able to address the patients 
concern. In the case of a patient waiting for results if they are unable to get in with the ordering 
physician until 2 months out of getting tested they will have to wait that long for results, which 
we know provokes anxiety and is one of the barriers to getting tested. This new rule may also 
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increase testing in the ED, as emergency physicians will not be reluctant to order test that have 
the potential to use up valuable time to counsel patients or wait for results. The ED sees its fair 
share of patients seeking testing for STIs, and from the studies observed in this paper, people 
who have been tested for STIs are more likely to get tested for HIV. Meaning that if we remove 
the barrier of ED physicians ordering HIV we can potentially increase HIV testing rates. For the 
following proposed solutions requires that it not be mandatory for results be communicated to 
individuals in person as it is only feasible if Kentucky statutes allow. 
At home testing should be an optional method of HIV screening in addition to on site testing. In 
addition to the Kentucky changes mentioned above this is only feasible if there is a change in 
federal healthcare policy making at-home HIV screening covered under insurance. From the 
studies evaluated in this paper we know that the convenience, privacy and anonymity are 
significant reasons why individuals opt for home testing, however with test costing upward of 
$40 cost can be a barrier. I propose that physicians be allowed to write prescriptions for at-home 
HIV Test covered by their insurance the patient can then go to the pharmacy, have the 
pharmacist explain how to use the test if patient request an explanation. However this leaves a 
possibility for the patient to not bring the results to their physician. To help incentivize patients 
to return results to their provider the insurance company may pass on cost of the test onto their 
next monthly premium and refund it as soon as the patient brings results to their provider who 
reports it to their insurance company. This allows for providers to report positive results (after 
confirmatory test) allowing for surveillance by the state health department and local health 
departments to perform contact investigation. Having the individual return to office with results 
will also give him the benefits of counselling, referral to resources and treatment. Even if the 
29 
 
patient/individual does not return results studies have shown that getting tested reduces risky 
behavior and therefore reduce risk of transmission (45). 
Now for the test I believe that the DPP HIV-1/2 Assay would be the best choice in regards to test 
to be offered. As we know the oral saliva test in general is one of the simplest and more preferred 
method of testing. It is the 2nd cheapest test and 3rd fastest test only taking 10 minutes for the 
results. Though other rapid test like the OraQuick and INSTI may be able to detect Abs sooner it 
is still recommended for all screening test to wait three months after exposure to screen for HIV 
which is well past the average time it takes to seroconvert. The test can be performed on-site or 
at home as well. 
This proposal is geared toward general rural Kentucky population who is at increased risk for 
rapid dissemination of HIV due to the prevalence of PWID. 
Table 4. Table of basic criteria to be considered with proposal. 
Area of Concern  How Concerns Are Addressed 
Barriers to Patient Testing Current Practices Proposed Practices 
Lack of Total Anonymity None Home testing. 
Venipuncture Various methods Various methods 
Anxiety waiting for results Rapid Test Rapid Test 
Post-test Counselling None Home Testing 
Testing Uncertainty Pre-Test Counselling Pre-Test Counselling 
Cost Insurance Insurance 
Barriers to Physicians 
Testing 
  
Time Consumption None (prior to 2019) Change to KRS 214.625 
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Limitations 
To try and create a solution to increasing HIV testing in any population involves a lot more than 
just changing policy at the state and federal level. It involves many other important components 
such as number of providers in the region, cultural and religious beliefs, transportation, 
technology, etc. None of which was addressed in this paper.  
Studies: Lack of comparable rural acceptability studies, of comparable acceptability studies in 
Kentucky, acceptability studies in the PWID population. Lack of multiple studies on policy 
changes to increase testing to compare.  
General information: Unknown type of testing in private clinics in rural Kentucky. Unknown 
stance on home testing for several private insurance companies. Did not compare cost of testing 
to conventional blood and urine test. 
Test: The DPP HIV ½ Assay is approved by the FDA to be used only by an agent of a clinical 
laboratory. 
Other limitations in regards to information is that specific information regarding what test was 
specifically used by certain government sponsored agencies were not discussed. 
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